

# Global Cancer Immunotherapy Market Outlook 2020

<https://marketpublishers.com/r/G95FBBB1B98EN.html>

Date: June 2015

Pages: 2600

Price: US\$ 3,600.00 (Single User License)

ID: G95FBBB1B98EN

## Abstracts

**Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.**

Immune system is an intricate network of various tissues, organs and cell that prevents the attack by infectious agents. It prevents the growth and development of pathogens in body that may cause disease development. Wide array of potential disease causing microorganism like bacteria, fungus and virus are identified and eliminated in the body. Immune system also has ability to identify self from foreign cells due to which transplant rejection is observed. It has capability to generate memory that helps in providing long-term memory. Dead and abnormal cell are removed from the body that may hinder the normal functioning of cellular processes. It could also be trained to identify and eliminate particular cells from the body by giving suitable cues. Investigators have utilized this property of immune system to treat diseases by modulating immune responses. Investigators have extended this modality for preventing cancer progression and proliferation by stimulating patients' immune system.

Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects.

Cancer immunotherapeutics segment seems to be quite dynamic as it has received

highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years.

Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts.

Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data.

New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future.

Cancer Immunotherapies Included in Report:

Adoptive Cell Transfer , GM-CSF, Immune Checkpoint Inhibitors, Immunomodulators, Interleukins, Interferon, Monoclonal Antibodies, Vaccines

'Global Cancer Immunotherapy Market Outlook 2020' Report Highlight:

Introduction & Classification of Cancer Immunotherapy

Global Cancer Immunotherapy Pipeline by Company, Indication & Phase

Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication

Global Cancer Immunotherapy Pipeline: 1834 Drugs

Marketed Cancer Immunotherapies: 113 Drugs

Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb

Cancer Vaccines Pipeline: 312 Vaccines

Marketed Cancer mAb: 36 mAb

Marketed Cancer Vaccines: 12 Vaccines

## Contents

### **1. INTRODUCTION TO CANCER IMMUNOTHERAPY**

### **2. CLASSIFICATION OF CANCER IMMUNOTHERAPY**

2.1 Specific Cancer Immunotherapy

2.2 Non-Specific Cancer Immunotherapy

### **3. CANCER IMMUNOTHERAPY BY VACCINES**

3.1 Introduction

3.2 Mechanism of Vaccines in Cancer Immunotherapy

3.2.1 Idiotype Cancer Vaccine Mechanism

3.2.2 Cellular Cancer Vaccines Mechanism

3.2.3 Ganglioside Antigens based Cancer Vaccines Mechanism

3.2.4 Peptide Cancer Vaccine Mechanism

3.2.5 Tumor Host Interaction Cancer Vaccine Mechanism

### **4. CANCER IMMUNOTHERAPY BY MONOCLONAL ANTIBODIES**

4.1 Introduction

4.2 Mechanism of Monoclonal Antibodies in Cancer Immunotherapy

### **5. CANCER IMMUNOTHERAPY BY ADOPTIVE CELL TRANSFER**

5.1 Introduction

5.2 Mechanism of Adoptive Cell Transfer Cancer Immunotherapy

### **6. CANCER IMMUNOTHERAPY BY IMMUNE CHECKPOINT INHIBITORS**

6.1 Introduction

6.2 Mechanism of Immune Checkpoint Inhibitors in Cancer Immunotherapy

### **7. CANCER IMMUNOTHERAPY BY IMMUNOMODULATORS**

7.1 Introduction

7.2 Mechanism of Immunomodulators in Cancer Immunotherapy

## **8. CANCER IMMUNOTHERAPY BY CYTOKINES**

- 8.1 Introduction
- 8.2 Mechanism of Cytokines Cancer Immunotherapy

## **9. CANCER IMMUNOTHERAPY BY INTERLEUKINS**

- 9.1 Introduction
- 9.2 Mechanism of Interleukinsin Cancer Immunotherapy

## **10. CANCER IMMUNOTHERAPY BY INTERFERON**

- 10.1 Introduction
- 10.2 Mechanism of Interferon Cancer Immunotherapy

## **11. CANCER IMMUNOTHERAPY BY GM-CSF**

- 11.1 Introduction
- 11.2 Mechanism of GM-CSF Cancer Immunotherapy

## **12. CANCER IMMUNOTHERAPY MARKET OVERVIEW**

- 12.1 Current Market Scenario
- 12.2 Cancer Immunotherapy Pipeline Overview

## **13. GLOBAL CANCER IMMUNOTHERAPY MARKET DYNAMICS**

- 13.1 Favorable Market Parameters
- 13.2 Commercialization Challenges

## **14. GLOBAL CANCER IMMUNOTHERAPY MARKET FUTURE PROSPECTS**

## **15. CANCER CELL THERAPIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 15.1 Unknown
- 15.2 Research
- 15.3 Preclinical
- 15.4 Clinical

- 15.5 Phase-I
- 15.6 Phase-I/II
- 15.7 Phase-II
- 15.8 Phase-III
- 15.9 Preregistration

## **16. MARKETED CANCER CELL THERAPIES DRUGS CLINICAL INSIGHT**

- 16.1 Sipuleucel-T (Provenge®)
- 16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)

## **17. CANCER CYTOKINES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 17.1 Unknown
- 17.2 Research
- 17.3 Preclinical
- 17.4 Clinical
- 17.5 Phase-I
- 17.6 Phase-I/II
- 17.7 Phase-II
- 17.8 Phase-III

## **18. MARKETED CANCER CYTOKINES DRUGS CLINICAL INSIGHT**

- 18.1 Aldesleukin (Proleukin®)
- 18.2 Denileukin Diftitox (ONTAK®)
- 18.3 Interferon Alpha (Multiferon®)
- 18.4 Interferon Alpha-2a (Roferon-A®)
- 18.5 Interferon Alpha-2a (Veldona®)
- 18.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
- 18.7 Interferon Alpha-2b(Intron® A)
- 18.8 Interferon Alpha-2b Biosimilar(Bioferon™)
- 18.9 Interferon Alpha-2b Biosimilar (Intalfa®)
- 18.10 Interferon Alpha-2b Biosimilar
- 18.11 Interferon-Alpha-n3 (Alferon N®)
- 18.12 Interferon-Beta-1b (Feron®)
- 18.13 Interferon-Gamma (Ogamma®)
- 18.14 Interleukin-2 Biosimilar (Ilcass)

18.15 Teceleukin (Imunace™)

## **19. CANCER IMMUNOMODULATORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

19.1 Unknown

19.2 Research

19.3 Preclinical

19.4 Clinical

19.5 Phase-I

19.6 Phase-I/II

19.7 Phase-II

19.8 Phase-II/III

19.9 Phase-III

19.10 Preregistration

19.11 Registered

## **20. MARKETED CANCER IMMUNOMODULATORS CLINICAL INSIGHT**

## **21. CANCER VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

21.1 Research

21.2 Preclinical

21.3 Clinical

21.4 Phase-I

21.5 Phase-I/II

21.6 Phase-II

21.7 Phase-II/III

21.8 Phase-III

21.9 Preregistration

21.10 Registered

## **22. MARKETED CANCER VACCINES CLINICAL INSIGHT**

22.1 Bladder Cancer Vaccine (PACIS®)

22.2 Bladder Cancer Vaccine

22.3 BV NSCLC

22.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)

22.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)

- 22.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
- 22.7 Melanoma Vaccine (MVax®)
- 22.8 Melanoma Vaccine (Melacine®)
- 22.9 Racotumomab (Vaxira®)
- 22.10 Sipuleucel-T (Provenge®)
- 22.11 Tertomotide (LucaVax)
- 22.12 Vitespen (Oncophage®)

## **23. CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 23.1 Unknown
- 23.2 Research
- 23.3 Preclinical
- 23.4 Clinical
- 23.5 Phase-I
- 23.6 Phase-I/II
- 23.7 Phase-II
- 23.8 Phase-II/III
- 23.9 Phase-III
- 23.10 Preregistration
- 23.11 Registered

## **24. MARKETED CANCER MONOCLONAL ANTIBODIES DRUGS CLINICAL INSIGHT**

## **25. COMPETITIVE LANDSCAPE**

- 25.1 Abbvie
- 25.2 Advaxis
- 25.3 Altor BioScience
- 25.4 Amgen
- 25.5 Biogen Idec
- 25.6 Biogenomics
- 25.7 Celldex Therapeutics
- 25.8 Dendreon Corporation
- 25.9 Eli Lilly
- 25.10 Expression Genetics
- 25.11 Galena Biopharma



- 25.12 Genmab
- 25.13 Gilead Sciences
- 25.14 GlaxoSmithKline
- 25.15 ImmunoCellular Therapeutics
- 25.16 ImmunoGen
- 25.17 Inovio Pharmaceuticals
- 25.18 IRX Therapeutics
- 25.19 Merck
- 25.20 NeoStem Oncology
- 25.21 NewLink Genetics
- 25.22 Northwest Biotherapeutics
- 25.23 Novartis
- 25.24 Peregrine Pharmaceuticals
- 25.25 Pfizer
- 25.26 Philogen
- 25.27 Regulon
- 25.28 Roche
- 25.29 Seattle Genetics
- 25.30 ZymoGenetics

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Functions of Immune System
- Figure 1-2: Necessity of Cancer Immunotherapies
- Figure 1-3: Benefits of Cancer Immunotherapies
- Figure 2-1: Classification of Cancer Immunotherapies
- Figure 2-2: Specific Cancer Immunotherapies
- Figure 2-3: Non-Specific Cancer Immunotherapies
- Figure 3-1: Categorization & Function of Cancer Vaccines
- Figure 3-2: Classification of Different Types of Cancer vaccines
- Figure 4-1: Development of Monoclonal Antibody
- Figure 4-2: Principle of Monoclonal Antibodies for Cancer Immunotherapy
- Figure 4-3: Type of Cancer Monoclonal Antibodies
- Figure 4-4: Mechanism of Alemtuzumab
- Figure 4-5: Mechanism of Ibritumomab Tiuxetan
- Figure 4-6: Mechanism of Blinatumomab
- Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy
- Figure 5-2: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
- Figure 5-3: Tumor-Infiltrating Lymphocytes Adoptive Cell Transfer Cancer Immunotherapy
- Figure 5-4: Mechanism of CAR Modified T-Cells
- Figure 5-5: Genetically Engineered TCR for Cancer Immunotherapy
- Figure 6-1: Benefits of Immune Checkpoint Inhibitors
- Figure 6-2: Mechanism of Ipilimumab
- Figure 6-3: Mechanism of Nivolumab
- Figure 6-4: Mechanism of Pembrolizumab
- Figure 7-1: Functions of Immunomodulators
- Figure 7-2: Benefits of Immunomodulators
- Figure 7-3: Limitations of Immunomodulators
- Figure 7-4: Mechanism of Thalidomide
- Figure 7-5: Mechanism of Lenalidomide In Vivo
- Figure 7-6: Mechanism of Lenalidomide In Vitro
- Figure 7-7: Mechanism of Pomalidomide
- Figure 8-1: Functions of Cytokine
- Figure 8-2: Benefits of Cytokine in Cancer Immunotherapy
- Figure 9-1: Functions of Interleukin
- Figure 9-2: Benefits of Interleukins in Cancer Immunotherapy

- Figure 9-3: Mechanism of Proleukin
- Figure 9-4: Mechanism of Denileukin Diftitox
- Figure 10-1: Major Types of Cytokine
- Figure 10-2: Functions of Interferon
- Figure 10-3: Classification of Interferons on the Basis of Types of Genes
- Figure 10-4: General Mechanism of Interferons
- Figure 10-5: Mechanism of Interferon Alfa-n3
- Figure 10-6: Mechanism of Peginterferon Alfa-2a
- Figure 10-7: Mechanism of Interferon Beta 1a
- Figure 10-8: Mechanism of Interferon Alfa-2b
- Figure 11-1: Usage of GM-CSF
- Figure 11-2: Mechanism of Sargramostim
- Figure 12-1: Cancer Immunotherapy Pipeline by Phase (%), 2015
- Figure 12-2: Cancer Immunotherapy Pipeline by Phase (Number), 2015
- Figure 12-3: Cancer Cytokines Pipeline by Phase (%), 2015
- Figure 12-4: Cancer Cytokines Pipeline by Phase (Number), 2015
- Figure 12-5: Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
- Figure 12-6: Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
- Figure 12-7: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
- Figure 12-8: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
- Figure 12-9: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
- Figure 12-10: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
- Figure 12-11: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
- Figure 12-12: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
- Figure 12-13: Cancer Vaccine Pipeline by Phase (%), 2015
- Figure 12-14: Cancer Vaccine Pipeline by Phase (Number), 2015
- Figure 12-15: No Development Reported Cancer Vaccine Pipeline by Phase (%), 2015
- Figure 12-16: No Development Reported Cancer Vaccine Pipeline by Phase (Number), 2015
- Figure 12-17: Discontinued Cancer Vaccine Pipeline by Phase (%), 2015
- Figure 12-18: Discontinued Cancer Vaccine Pipeline by Phase (Number), 2015
- Figure 12-19: Suspended Cancer Vaccine Pipeline by Phase (%), 2015
- Figure 12-20: Suspended Cancer Vaccine Pipeline by Phase (Number), 2015
- Figure 12-21: Cancer Immunomodulators Pipeline by Phase (%), 2015
- Figure 12-22: Cancer Immunomodulators Pipeline by Phase (Number), 2015

Figure 12-23: Cancer Cell Therapies Pipeline by Phase (%), 2015

Figure 12-24: Cancer Cell Therapies Pipeline by Phase (Number), 2015

Figure 12-25: Discontinued Cancer Cell Therapies Pipeline by Phase (%), 2015

Figure 12-26: Discontinued Cancer Cell Therapies Pipeline by Phase (Number), 2015

Figure 13 1: Favorable Cancer Immunotherapy Market Parameters

Figure 13 2: Cancer Immunotherapy Commercialization Challenges

Figure 25-1: Advaxis Clinical Pipeline

Figure 25-2: Celldex Therapeutics Clinical Pipeline

Figure 25-3: Expression Genetics Clinical Pipeline

Figure 25-4: Galena Biopharma Clinical Pipeline

Figure 25-5: ImmunoCellular Therapeutics Clinical Pipeline

Figure 25-6: ImmunoGen Clinical Pipeline

Figure 25-7: Inovio Pharmaceuticals Clinical Pipeline

Figure 25-8: NewLink Genetics Corporation Clinical Pipeline

Figure 25-9: Northwest Biotherapeutics Clinical Pipeline

Figure 25-10: Peregrine Pharmaceuticals Clinical Pipeline

Figure 25-11: Philogen Clinical Pipeline

Figure 25-12: Seattle Genetics Clinical Pipeline

## List Of Tables

### LIST OF TABLES

Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy

Table 6-1: Some Important Checkpoint Inhibitors

Table 8-1: Few Important Immunocytokines under Clinical Development

Table 8-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies

Table 12-1: Few Commercially Important PD-1 Drugs

## I would like to order

Product name: Global Cancer Immunotherapy Market Outlook 2020

Product link: <https://marketpublishers.com/r/G95FBBB1B98EN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G95FBBB1B98EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970